Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dacarbazine + doxorubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- Southern Research
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen consists of three cytotoxic agents—dacarbazine, doxorubicin, and ifosfamide—used primarily for the treatment of advanced or metastatic soft tissue sarcomas. The regimen is notable for its high response rates compared to single-agent or two-drug combinations in this setting. Doxorubicin intercalates into DNA and inhibits topoisomerase II; ifosfamide is an alkylating agent that cross-links DNA strands; dacarbazine also acts as an alkylating agent and antimetabolite. The combination has been evaluated in clinical trials for efficacy and safety in sarcoma patients.
- Other names
- doxorubicin plus dacarbazine plus ifosfamideADI regimenMAID (with mesna)DTIC-doxorubicin-ifosfamide
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on dacarbazine + doxorubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dacarbazine + doxorubicin + ifosfamide.